Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
Inmune Bio, Inc. (INMB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "INMUNE BIO Inc. AMENDMENT NO. 1 TO At-the-market SALES AGREEMENT",
"OPINION OF SICHENZIA ROSS FERENCE LLP"
08/16/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2023 8-K Quarterly results
Docs: "INMUNE BIO INC. CONSOLIDATED BALANCE SHEETS"
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Quarterly results
07/27/2023 8-K Other Events  Interactive Data
07/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:",
"Investor Contact:",
"Investor Contact:"
07/12/2023 144 Form 144 - Report of proposed sale of securities:
06/01/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan"
05/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation"
05/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BOCA RATON, Fla., May 08, 2023 -- INmune Bio, Inc."
05/04/2023 8-K Quarterly results
Docs: "PRESS RELEASE FOR FINANCIAL RESULTS AND BUSINESS UPDATE"
04/24/2023 8-K Quarterly results
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 8-K Quarterly results
04/03/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "[email protected] Investor"
03/20/2023 4 Moss David J (CFO, Treasurer & Secretary) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 2,500 shares @ $6.425, valued at $16.1k
03/15/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation"
03/02/2023 10-K Annual Report for the period ended December 31, 2022
02/22/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact: Jason Nelson Core IR 842-9614 x-823"
02/22/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/10/2023 8-K Quarterly results
01/25/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "INmune Bio, Inc. , a clinical-stage immunology company focused on developing treatments that harness the patient’ s innate immune system to fight disease, in collaboration with Professor Armando Villalta, Ph.D. of University California, Irvine School of Medicine, has shown targeting soluble TNF using a Dominant-Negative TNF biologic significantly decreased muscle damage in a murine mdx model of Duchenne Muscular Dystrophy and showed a statistically significant increase in muscle regeneration. Current clinical approaches to limiting muscle damage and inflammation in DMD patients, such as corticosteroids, can be immunosuppressive and promote metabolic problems, leading to significant long-term side effects including muscle atrophy with chronic use. There are currently no approved drugs that ..."
12/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "INmune Bio, Inc. is a publicly traded , clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer , Mild Alzheimer’ s disease, Mild Cognitive Impairment and treatment-resistant depression . The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’ s NK cells to eliminate minimal residual disease in patients with c..."
12/12/2022 8-A12B/A Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]
12/12/2022 8-K Quarterly results
12/09/2022 8-K Quarterly results
12/07/2022 8-K Quarterly results
11/29/2022 8-K Quarterly results
11/21/2022 8-K Quarterly results
11/04/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
11/02/2022 10-Q Quarterly Report for the period ended September 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy